Skip to content

April 27, 2026

Home
Signal News
Biopharma Brief
Week in Review
Contact

Light/Dark Button

Search for:

Home
Other
GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

Pharmaphorum

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.

Read full story

pharminent April 27, 2026 (Last updated: April 27, 2026)

Pharmaphorum

A court ruling in the US has delivered a setback for GSK and its Tesaro subsidiary in their dispute with AnaptysBio over cancer drug Jemperli.

Read full story

Post navigation

Previous: Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

Related Stories

Other

New NIHR-funded TRC for Parkinson’s disease

pharminent April 27, 2026

Other

UK biotech could be bound for recovery, BIA report reveals

pharminent April 27, 2026

Other

MSD teams up with Google Cloud on agentic AI transformation

pharminent April 23, 2026

You May Have Missed

Other

GSK/Tesaro claim denied in Jemperli lawsuit with AnaptysBio

pharminent April 27, 2026

Pipeline

Rejuvenate crowdfunds development of gene therapy for aging, chronic diseases

pharminent April 27, 2026

Policy / Pricing

J&J puts blockbuster blood thinner Xarelto on TrumpRx

pharminent April 27, 2026

M&A / Deals

Eli Lilly acquires Ajax Therapeutics for first-in-class JAK2 inhibitor in myelofibrosis

pharminent April 27, 2026

Copyright © 2026 All rights reserved. | ReviewNews by AF themes.